Table 1 Patient characteristics

From: Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

 

Patients (n = 44)

Age, year (median, range)

61 (43–78)

BMI, kg/m2 (median, range)

22.9 (16.7–30.1)

Histology subtype

   High-grade serous carcinoma

41 (93.2%)

   Low-grade serous carcinoma

1 (2.3%)

   Clear cell carcinoma

1 (2.3%)

   Endometrioid carcinoma

1 (2.3%)

FIGO stage at diagnosis

   I or II

6 (13.6%)

   III or IV

38 (86.4%)

Time to progression after penultimate platinum therapy

   6–12 months

12 (27.3%)

   12–24 months

21 (47.7%)

   24+ months

11 (25.0%)

Best response to most recent platinum therapy

   CR

11 (25.0%)

   PR

33 (75.0%)

Maintenance after first-line chemotherapy

   Bevacizumab

9 (20.5%)

   Olaparib

1 (2.3%)

HRD score (genomic instability score)

   <42

18 (40.9%)

   ≥42

24 (54.6%)

   Missing

2 (4.5%)

PD-L1 CPS

   <1

15 (34.1%)

   ≥1

28 (63.6%)

   Missing

1 (2.3%)

  1. BMI Body mass index, FIGO International Federation of Gynecology and Obstetrics, CR Complete response, PR Partial response, HRD Homologous recombination deficiency, PD-L1 CPS Programmed death ligand-1 combined positive score.
Back to article page